Clincosm LogoSign in Get a demo

We-Longevity: Westlake Longevity Cohort

Sponsor
Westlake University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05256251
Collaborator
The Sixth Affiliated Hospital of Wenzhou Medical University (Other)
2,400
Enrollment
1
Location
120
Anticipated Duration (Months)
20
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians, senior citizens and their family members up to three generations living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. Another aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity are influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome and genetics. At present, the researches on healthy longevity are mainly focused on Drosophila, nematodes and mouse models, and few studies on longevity population. Centenarians and nonagenarians are the best objects to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanism of healthy longevity in human are still unclear. There, the present We-Longevity design includes 200 centenarians, 600 nonagenarians, 400 senior citizens and 1200 family members up to three generations. We will determine the fecal/serum metabolome, gut microbiome serum proteome and genome, together with diet, lifestyle and disease information. We will then follow up the centenarians every six months.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    2400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Westlake Longevity Cohort
    Actual Study Start Date :
    Nov 15, 2021
    Anticipated Primary Completion Date :
    Nov 14, 2024
    Anticipated Study Completion Date :
    Nov 14, 2031

    Outcome Measures

    Primary Outcome Measures

    1. aging [36 months]

      Physical frailty will be evaluated by using Fried's criteria.

    2. Gut microbiota [36 months]

      Fecal microbiome will be analyzed by 16S rRNA gene sequencing and metagenome sequencing.

    3. Metabolomics of serum and gut microbiome [36 months]

      Metabolomics of serum and gut microbiome will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).

    4. Proteomic profiling of serum [36 months]

      Proteomic characterization of serum will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).

    5. Genome [36 months]

      Genomic characterization will be analyzed by Illumina ASA-750K arrays.

    Secondary Outcome Measures

    1. Cognitive function [36 months]

      Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).

    2. Blood glucose examination of blood samples [36 months]

      Blood glucose will be analyzed by automatic biochemical analyser.

    3. Blood blood lipids examination of blood samples [36 months]

      Blood blood lipids (HDL, LDL, TC and TG) will be analyzed by automatic biochemical analyser.

    4. Serum cytokines examination of blood samples [36 months]

      Serum cytokines (IFNγ, IL10, IL12p70, IL13, IL1β, IL2, IL4, IL6, IL8 and TNFα) will be analyzed by electrochemiluminescence immunoassay.

    5. Serum neurotranszmitters examination of blood samples [36 months]

      Serum neurotranszmitters (dopamine, choline, acetyl choline, tyramine, tryptamine, 5-hydroxyindoleacetic acid, phenylpyruvic acid, 3,4-dihydroxyphenylacetic acid and 3-hydroxyo-aminobenzoic acid) will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Participants aged 50 years or order.

    • Participants live in Lishui, China.

    • Participants intend to remain in Lishui for ≥3 years.

    Exclusion Criteria:
    • Participants with cancer, serious medical disorders or infectious diseases.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Lishui City People's Hospital Lishui Zhejiang China 323000

    Sponsors and Collaborators

    • Westlake University
    • The Sixth Affiliated Hospital of Wenzhou Medical University

    Investigators

    • Principal Investigator: Ju-Sheng Zheng, PhD, Westlake University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Westlake University
    ClinicalTrials.gov Identifier:
    NCT05256251
    Other Study ID Numbers:
    • 20211015ZJS001
    First Posted:
    Feb 25, 2022
    Last Update Posted:
    Jun 16, 2022
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Alzheimer Disease
    Neurodegenerative Diseases

    Study Results

    No Results Posted as of Jun 16, 2022